Sources and approach
Sources and approach
Each record links to its references. The public catalogue is synchronized from ClinicalTrials.gov and shows the source date, its limits and the review status.
Scientific and editorial charter
RE2T references, explains and contextualizes primary sources. RE2T does not conduct research, recruit for trials or give medical advice.
Read statuses separately: primary source, RE2T summary, AI-assisted translation, source check, editorial review, scientific review and medical validation. Medical validation is shown only when the professional’s identity and qualification are verified.
API: public catalogue synchronized, with source date and review status shown
Consulted · Sep 8, 2026
FDAThe drug development processFDAClinical researchEMAAuthorisation of medicinesClinicalTrials.govStudy status definitionsNINDS / NIHRett syndromeEMAClinical Trials RegulationClinicalTrials.govAPI v2 · DocumentationEurope PMCArticles RESTful API · DocumentationClinicalTrials.gov · NCT05606614TSHA‑102 · REVEALClinicalTrials.gov · NCT05898620NGN‑401 · EmboldenClinicalTrials.gov · NCT07503444Fenfluramine · Phase 3ClinicalTrials.gov · NCT07430046Mirtazapine · MirtaRettClinicalTrials.gov · NCT04181723Trofinetide · LAVENDERClinicalTrials.gov · NCT04988867Trofinetide · DAFFODILScience Translational Medicine · PMID 40173263Self-regulating gene therapy ameliorates phenotypes and overcomes gene dosage sensitivity in a mouse model of Rett syndromeMed · PMID 40043705Results from the phase 2/3 DAFFODIL study of trofinetide in girls aged 2–4 years with Rett syndromeNature Medicine · PMID 37291210Trofinetide for the treatment of Rett syndrome: a randomized phase 3 studyRE2TMentions légales officiellesRE2TPolitique de confidentialité officielleRE2TAccessibilité officielle
Sources consulted on 8 September 2026 · AI-assisted summaries and translations, not medically validated.